Matthew Fowler | Authors

Articles

Daratumumab/CyBorD Followed By Maintenance Leads to Deep Responses in Multiple Myeloma

June 21, 2021

Results from the LYRA trial showed that the combination of daratumumab with cyclophosphamide, bortezomib, and dexamethasone induction followed by daratumumab maintenance therapy achieved durable and deep responses in patients with newly diagnosed or relapsed multiple myeloma, regardless of transplant status.

Deep Remission Achieved with Daratumumab Plus CyBorD Followed by Daratumumab Maintenance for Multiple Myeloma

June 19, 2021

Daratumumab plus cyclophosphamide, bortezomib, and dexamethasone induction followed by daratumumab maintenance therapy achieved durable and deep responses in patients with newly diagnosed or relapsed multiple myeloma, regardless of transplant status.

Cilta-Cel Significantly Improves Responses for Triple-Class Exposed Myeloma Patients

June 13, 2021

Patients with triple-class exposed relapsed or refractory multiple myeloma demonstrated greater efficacy in terms of response and survival from treatment with ciltacabtagene autoleucel in comparison with the standard of care (SOC) in the CARTITUDE-1 trial, according to findings presented at the 2021 EHA Congress.

Cilta-Cel Outperforms Conventional Therapies in R/R Multiple Myeloma

June 11, 2021

Outcomes for patients with relapsed or refractory multiple myeloma who had previously received a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody improved with the use of ciltacabtagene autoleucel as compared with conventional therapies, according to findings from propensity score–matched analyses of the CARTITUDE-1 and MAMMOTH studies.